INTRODUCTION
============

Pheochromocytoma and paraganglioma (PPGL) are neuroendocrine tumors from chromaffin cells and usually originated from the medulla of the adrenal gland or extra-adrenal location in which chromaffin cells are located \[[@b1-kjim-2018-231],[@b2-kjim-2018-231]\]. PPGLs release catecholamines into circulation, and these can be related to episodic headache, dizziness and palpitation as results of stimulation of beta-adrenergic receptors. Because alpha-adrenergic stimulation can cause elevation of blood pressure (BP), PPGLs are considered one of causes of secondary hypertension. Moreover, excessive catecholamine release increases heart rate and can provoke transient cardiomyopathy (CMP) associated with catecholamine \[[@b3-kjim-2018-231],[@b4-kjim-2018-231]\]. However, diagnosis of PPGLs is quite challenging because their clinical manifestations are nonspecific and variable, and they are rare tumors. Since widespread use of computed tomography (CT) scans, especially for the purpose of health screening, has led to increased rate of detection of adrenal tumors without symptoms (incidentalomas), the prevalence of clinical presentations suggesting catecholamine excess might have changed from past studies in patients with PPGLs. Thus, we evaluated the clinical presentations of patients with surgically resected PPGLs.

METHODS
=======

Study population
----------------

All consecutive patients with PPGLs which were surgically resected and confirmed by pathologic examination were retrospectively enrolled from January 2005 to December 2017 in two tertiary teaching hospitals in Korea (Chungnam National University Hospital \[CNNUH\] and Chonbuk National University Hospital \[CBNUH\]).

Study measures
--------------

The baseline demographic characteristics including age, sex, past history of hypertension and antihypertensive medication, clinical symptoms, levels of urinary and plasma catecholamines, and radiologic findings including CT were investigated with the review of medical records. Excretion of 24-hour urinary catecholamines and levels of plasma catecholamines were measured by a liquid chromatographic method (reference, 24-hour urinary norepinephrine \< 80 μg/day, epinephrine \< 22 μg/day, vanillyl mandelic acid \[VMA\] \< 8 mg/day, metanephrine \< 0.8 mg/day, plasma free metanephrine \< 0.50 nmol/L, normetanephrine \< 0.90 nmol/L, epinephrine 1 to 20 pg/mL, and norepinephrine 15 to 80 pg/mL) \[[@b5-kjim-2018-231]\]. Catecholamine secretion was considered to be significantly increased if the 24-hour urinary excretion of metanephrine, epinephrine or norepinephrine, or plasma levels of metanephrine or normetanephrine was five times higher than their cut-off values.

Electrocardiographic (ECG) findings were classified into four categories: left ventricular hypertrophy by voltage criteria, significant ST-T abnormalities, nonspecific ST-T changes, and normal ECG. Presence of CMP was defined as echocardiographic evidence of left ventricular dysfunction and regional wall motion abnormalities (RWMA) inconsistent with coronary territories or transient RWMA with no evidence of obstructive coronary lesions. The tumor with the presence of local invasion into surrounding organs and tissues or distant metastases was considered to have malignant potential. This study protocol was approved by Institutional Review Board of each hospital (IRB No. CNNUH, 2016-12-047; CBNUH, 2018-07-002) and written informed consent was waived because the study was retrospective and anonymous clinical data were used for analysis.

Statistical analysis
--------------------

Data are expressed as mean ± standard deviation for continuous variables and as frequencies (percentages) for the categorical variables. Statistical analysis was performed using SPSS version 22.0 (IBM Inc., Chicago, IL, USA) software. A Mann-Whitney *U* test and Student's *t* test were performed for statistical comparison between the numeric data, while a chi-square test was performed for the categorical data. Statistical significance was determined as a *p* value \< 0.05.

RESULTS
=======

Clinical characteristics of overall patients with PPGLs
-------------------------------------------------------

During the study period, a total of 111 patients with PPGLs were enrolled. Mean age was 52 ± 16 years (range, 14 to 81) and 57 patients (51.4%) were male. Mean systolic and diastolic BPs of overall patients were 133.2 ± 23.3 and 80.4 ± 15.0 mmHg, respectively. Fifty-four patients (48.6%) had a history of hypertension and 48 (45.3%) were taking 1.9 ± 0.8 antihypertensive drugs. Their mean BP at presentation was 137.3 ± 27.7/81.9 ± 16.6 mmHg.

ECG was normal in 78 patients (71.6%). Left ventricular hypertrophy by voltage criteria was noted in 22 patients (20.2%), significant ST-T abnormalities in seven (6.4%) and nonspecific ST-T changes in two (1.8%). Echocardiography was performed in 46 patients (41.8%) due to cardiovascular symptoms such as chest pain or dyspnea (n = 8), abnormal ECG (n = 14) or cardiovascular risk factors (n = 8), and for preoperative screening (n = 16). Mean left ventricular ejection fraction (LVEF) was 58.9% ± 10.0%.

Eighty-two patients (73.9%) had pheochromocytomas and 29 (26.1%) of PPGLs was extra-adrenal paragangliomas in the head and neck, chest, abdomen, and pelvis (middle ear, carotid body, aorta, retroperitoneum, duodenum, bladder, and scrotum). Twenty PPGLs (18.0%) showed malignant potential and four patients (3.6%) had metastatic lesions. After the surgery, 20 patients (18.2%) still needed 1.6 ± 0.9 antihypertensive medications and their BP was 124.8 ± 15.0/74.4 ± 7.1 mmHg.

Comparison of symptomatic PPGLs versus incidentalomas
-----------------------------------------------------

In 88 patients (79.3%), PPGLs were incidentally found during routine abdominal imaging. Other reasons of work-up for PPGLs were paroxysmal elevation of BP with clinical suspicion of secondary hypertension in 16 patients (14.4%) and transient CMP in seven patients (6.3%). We divided our study patients into two groups; 23 patients with clinical presentations of BP elevation or CMP were classified into Group 1 (suspected group) and the remainders (87 patients) who were diagnosed incidentally into Group 2 (incidental group). Their clinical characteristics and laboratory findings are listed in [Tables 1](#t1-kjim-2018-231){ref-type="table"} and [2](#t2-kjim-2018-231){ref-type="table"}.

Patients in the Group 1 were significantly younger than those in the Group 2 (44 ± 16 years old vs. 54 ± 15 years old, *p* = 0.005). Clinical symptoms related to catecholamine excess such as headache (52.2% vs. 6.8%, *p* \< 0.001), chest pain (39.1% vs. 4.5%, *p* \< 0.001), and palpitation (34.8% vs. 8.0%, *p* = 0.003) were more frequent in the Group 1 than in the Group 2. In the Group 1, systolic (147.5 ± 28.3 mmHg vs. 129.6 ± 20.6 mmHg, *p* = 0.012) and diastolic BP (93.1 ± 20.6 mmHg vs. 77.3 ± 11.3 mmHg, *p* = 0.002), and heart rate (84.4 ± 12.0 bpm vs. 76.5 ± 12.8 bpm, *p* = 0.014) were significantly higher than those in the Group 2. In terms of location, extra-adrenal paragangliomas were significantly less frequent in the Group 1 than the Group 2 (8.7% vs. 30.7%, *p* = 0.033) although the size of the tumor, malignant potential, presence of necrosis, and distant metastasis were comparable in the two groups ([Table 2](#t2-kjim-2018-231){ref-type="table"}). The levels of urinary excretion of metanephrine, epinephrine and VMA were significantly higher and increased secretion of epinephrine was more predominant (85.7% vs. 58.5%, *p* = 0.023) in Group 1 than in Group 2 ([Table 2](#t2-kjim-2018-231){ref-type="table"}). Patients in Group 1 showed significant ST-T abnormalities on ECG more frequently than those in Group 2 (21.7% vs. 2.3%, *p* = 0.003).

Clinical profiles of patients with catecholamine CMP
----------------------------------------------------

The clinical profiles of patients with CMP are summarized in [Table 3](#t3-kjim-2018-231){ref-type="table"}. The main symptom was chest pain. ST change and T-wave abnormalities were commonly found in the ECG examinations. Apical ballooning was found in four patients and inverted Takotsubo pattern (basal ballooning) was demonstrated in three patients in the echocardiographic studies. All patients with CMP recovered within 12 days (range, 3 to 12). One patient had cardiogenic shock and was successfully treated with extracorporeal membrane oxygenation for 12 days and continuous renal replacement therapy for 25 days ([Fig. 1](#f1-kjim-2018-231){ref-type="fig"}).

The clinical characteristics of patients presenting with CMP (n = 7) and those without CMP (n = 104) are shown in [Table 4](#t4-kjim-2018-231){ref-type="table"}. All tumors in patients with CMP were pheochromocytomas and their secretion of epinephrine was significantly increased. Patients with CMP had more frequent symptoms, history of hypertension, and higher diastolic BP than those without CMP, and showed trends of more frequent diabetes and dyslipidemia, poorer LVEF and higher need for antihypertensives after surgery ([Table 4](#t4-kjim-2018-231){ref-type="table"}).

DISCUSSION
==========

In this study, we examined 111 patients with surgically resected PPGLs and demonstrated that the majority (79.3%) of patients were diagnosed incidentally and 23 patients (20.7%) were diagnosed during work-up for other causes; 16 (14.4%) for evaluation of BP elevation and seven (6.3%) for work-up of CMP. In patients presented with hypertension or CMP, adrenal locations, increased secretion of epinephrine, and cardiovascular symptoms were more prominent than in those with incidentaloma.

PPGLs are catecholamine-producing tumors originated from chromaffin cells in the adrenal glands or along the extra-adrenal sympathetic ganglia. Typical symptoms associated with the secretion of catecholamine include headache, tachycardia, dizziness, and sweating \[[@b6-kjim-2018-231]\]. In our study, the frequency of symptoms associated with PPGLs and the levels of urinary excretion of catecholamines were significantly higher in the Group 1 than in the Group 2. These findings suggest that their symptoms were associated with the excess of catecholamines.

The reported incidence of hypertension is about 80% to 90% of patients with pheochromocytoma and half of them demonstrate sustained hypertension \[[@b7-kjim-2018-231],[@b8-kjim-2018-231]\]. However, recent popular use of CT imaging can increase the proportion of asymptomatic patients \[[@b9-kjim-2018-231]\] and about 5% to 6% of adrenal incidentalomas have been reported to be PPGLs \[[@b10-kjim-2018-231],[@b11-kjim-2018-231]\]. Therefore, hypertension can be absent in a substantial portion of patients with PPGLs \[[@b12-kjim-2018-231],[@b13-kjim-2018-231]\]. A German study \[[@b12-kjim-2018-231]\] including 201 patients diagnosed with PPGL between 1973 and 2007 showed that only 10% of cases presented the typical triad of symptoms; 29.4% of them were incidentally detected and incidentalomas were increasing in recent years. In our study, PPGLs were clinically suspected as a secondary cause of hypertension in only 14.4% of patients with PPGLs because of paroxysmal elevation of BP. Imaging studies done during routine health screening were the most common route of detection of PPGLs in this study. The incidence of hypertension was 48.6% and comparable in both groups. Out of 54 patients with a medical history of hypertension, 34 (63.0%) discontinued antihypertensive medication after the resection of the PPGLs (eight in the Group 1 and 20 in the Group 2). Meticulous history taking, application of imaging studies and biochemical screening can lead to early diagnosis of PPGL as a cause of secondary hypertension.

Another interesting finding of our study is that transient CMP was an initial presentation of PPGLs. The socalled catecholamine CMP presents transient, reversible cardiac dysfunction. Shaw et al. \[[@b14-kjim-2018-231]\] reported echocardiographic findings of transient CMP in a patient with pheochromocytoma in 1987. Catecholamine CMP can demonstrate typical transient apical ballooning \[[@b15-kjim-2018-231],[@b16-kjim-2018-231]\] or inverted Takotsubo-type CMP (transient mid- or basal ventricular ballooning) \[[@b4-kjim-2018-231],[@b17-kjim-2018-231]\]. Catecholamines can induce myocardial damage by microvascular dysfunction of the coronary arteries, multivessel epicardial spasm, impaired fatty acid metabolism, myocarditis and catecholamine-mediated myocardial dysfunction \[[@b17-kjim-2018-231],[@b18-kjim-2018-231]\]. Although a majority of patients with catecholamine CMP recover within several days, catecholamine toxicity may produce long-lasting myocardial alterations even after curative resection of PPGLs \[[@b19-kjim-2018-231]\]. The incidence of transient CMP was 6.3% in our study. All patients were clinically improved within 12 days after the onset of symptoms. One of our patients with CMP presented as a profound cardiogenic shock with basal ballooning requiring mechanical circulatory support ([Fig. 1](#f1-kjim-2018-231){ref-type="fig"}).

About 15% to 20% of PPGLs are derived from extra-adrenal chromaffin tissue referred to as paragangliomas and are known to not produce catecholamine \[[@b20-kjim-2018-231]\]. In our study, 26.1% of the PPGLs were extra-adrenal. The prevalence of paragangliomas was lower in Group 1 than in Group 2 (8.7% vs. 30.7%, *p* = 0.033) and all tumors associated with CMP were pheochromocytomas.

It has been suggested that predominant catecholamine can determine clinical manifestations of PPGLs \[[@b21-kjim-2018-231],[@b22-kjim-2018-231]\]. Increased plasma epinephrine has been reported to be associated with paroxysmal elevation of BP and norepinephrine with sustained hypertension \[[@b21-kjim-2018-231]\]. We demonstrated that the secretion of epinephrine and metanephrine was found to be significantly increased in patients in Group 1 compared to Group 2, although the levels were far above the upper normal values in both groups. This finding was more evident in patients with CMP, which were consistent with epinephrine-related toxic CMP. On the other hand, in patients without CMP, urinary excretion of norepinephrine and the level of plasma free normetanephrine were higher than in patients with CMP, although the rates did not reach statistical significance due to the small number of patients. This can partly be explained biochemically; extra-adrenal PPGLs are predominantly associated with secretion of norepinephrine and normetanephrine \[[@b10-kjim-2018-231]\].

Our study has several limitations. First, this study is a retrospective study through a review of medical records. Therefore, symptoms associated with catecholamine excess were not adequately described and not all levels of urinary and plasma catecholamines were measured. Because echocardiographic studies were performed in the selected patients with suspected cardiac dysfunction, the incidence and patterns of CMP could not be assessed exactly. PPGLs are very rare tumors and can be missed, especially when there are no apparent symptoms. To evaluate the exact incidence and pattern of the clinical presentations associated with PPGLs, a prospective cohort study will be needed.

KEY MESSAGE
===========

1\. Out of a total of 111 patients with surgically resected pheochromocytoma and paraganglioma (PPGL), seven (6.3%) presented with transient cardiomyopathy (CMP) and 16 (14.4%) with elevated blood pressure.

2\. Along with hypertension, transient CMP can be an initial presentation of PPGL.

3\. Location of tumor and secretion of catecholamine of may vary depending on the presence of symptoms in patients with PPGL.

No potential conflict of interest relevant to this article was reported.

![Representative case. A 40-year-old woman (Case no. 7) presented with acute dyspnea after dilation and curettage due to missed abortion. Her blood pressure was 80/50 mmHg and heart rate was 120 bpm. (A) Two-dimensional echocardiography on admission day showed basal dyskinesis with severely depressed left ventricular ejection fraction (LVEF) of 15% and global longitudinal strain (GLS) of −1.9%. (B) Two months after treatment with mechanical ventilation, extracorporeal membrane oxygenation and continuous renal replacement therapy, her LVEF was improved to 61% and GLS to −21.0%. Her urinary excretions of metanephrine and epinephrine were increased to 2.0 mg/day and 50.9 µg/day, respectively. Abdominal magnetic resonance imaging study showed a 2.8 × 2.4 cm-sized mass (arrows) at right suprarenal area with (C) low on T1-weighted and (D) high signal intensity on T2-weighted images. (E) ^123^I-metaiodobenzylguanidine (MIBG) single-photon emission computed tomography demonstrated intense MIBG uptake in the right adrenal mass (arrow) which was compatible with pheochromocytoma. ANT, anterior wall; SEPT, septum; INF, inferior wall; LAT, lateral wall; POST, posterior wall.](kjim-2018-231f1){#f1-kjim-2018-231}

###### 

Clinical characteristics of patients with surgically resected pheochromocytoma and paraganglioma at initial presentation and after surgery according to their clinical presentations

  Variable                         Total (n = 111)   Group 1 (n = 23)   Group 2 (n = 88)   *p* value
  -------------------------------- ----------------- ------------------ ------------------ -----------
  Baseline characteristics                                                                 
   Age, yr                         52 ± 16           44 ± 16            54 ± 15            0.005
   Male sex                        57 (51.4)         9 (39.1)           48 (54.5)          0.243
   History of hypertension         54 (48.6)         12 (52.2)          42 (47.7)          0.816
    Antihypertensive medications   48 (45.3)         14 (60.9)          34 (41.0)          0.090
    No. of pills                   1.9 ± 0.8         1.9 ± 0.6          1.9 ± 0.9          0.753
   Diabetes                        20 (18.0)         6 (26.1)           14 (15.9)          0.359
   Dyslipidemia                    11 (9.9)          3 (13.0)           8 (9.1)            0.695
  Vital signs at presentation                                                              
   SBP, mmHg                       133.2 ± 23.3      147.5 ± 28.3       129.6 ± 20.6       0.012
   DBP, mmHg                       80.4 ± 15.0       93.1 ± 20.6        77.3 ± 11.3        0.002
   HR, bpm                         78.0 ± 12.9       84.4 ± 12.0        76.5 ± 12.8        0.014
  Symptoms                                                                                 
   Headache                        18 (16.2)         12 (52.2)          6 (6.8)            \< 0.001
   Dizziness                       12 (10.8)         5 (21.7)           7 (8.0)            0.123
   Chest pain                      13 (11.7)         9 (39.1)           4 (4.5)            \< 0.001
   Palpitation                     15 (13.5)         8 (34.8)           7 (8.0)            0.003
  Postoperative clinical course                                                            
   SBP, mmHg                       123.3 ± 13.3      123.0 ± 11.2       123.4 ± 13.9       0.905
   DBP, mmHg                       75.0 ± 8.3        76.8 ± 7.6         74.5 ± 8.4         0.277
   HR, bpm                         76.0 ± 12.4       82.3 ± 12.9        74.5 ± 11.8        0.015
    Antihypertensive medications   20 (18.2)         6 (26.1)           14 (16.1)          0.269
    No. of pills                   1.6 ± 0.9         1.2 ± 0.4          1.8 ± 0.9          0.074

Values are presented as mean ± SD or number (%).

SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate.

###### 

Laboratory, electrocardiographic, and echocardiographic findings of patients with surgically resected pheochromocytoma and paraganglioma and their characteristics according to their clinical presentations

  Variable                                    Total (n =111)      Group 1 (n = 23)    Group 2 (n = 88)   *p* value
  ------------------------------------------- ------------------- ------------------- ------------------ -----------
  Characteristics of tumors                                                                              
   Location                                                                                              0.033
    Adrenal (pheochromocytoma)                82 (73.9)           21 (91.3)           61 (69.3)          
    Extra-adrenal (paraganglioma)             29 (26.1)           2 (8.7)             27 (30.7)          
   Maximal diameter (mm) in imaging studies   43.6 ± 31.0         41.9 ± 15.7         44.1 ± 33.8        0.778
   Presence of necrosis                       35 (31.5)           10 (43.5)           25 (28.4)          0.196
   Malignant potential                        20 (18.2)           4 (17.4)            16 (18.4)          0.912
   Metastatic lesions                         4 (3.6)             1 (4.3)             3 (3.4)            0.838
  Laboratory findings                                                                                    
   BUN, mg/dL                                 14.9 ± 6.1          15.6 ± 6.9          14.0 ± 5.8         0.281
   Serum creatinine, mg/dL                    0.9 ± 1.1           0.8 ± 0.3           0.9 ± 1.2          0.613
   Total cholesterol, mg/dL                   190.5 ± 40.8        201.0 ± 42.9        187.1 ± 39.8       0.154
   Urine metanephrine (\< 0.8), mg/day        123.1 ± 707.3       302.2 ± 1,238.5     61.3 ± 387.0       0.002
   Urine epinephrine (1.7--2.2), µg/day       118.6 ± 327.9       320.4 ± 586.5       43.5 ± 66.1        0.019
   Urine norepinephrine (12.1--80), µg/day    274.5 ± 339.7       292.8 ± 385.0       267.7 ± 334.6      0.693
   Urine VMA (\< 8), mg/day                   19.7 ± 33.3         25.3 ± 26.0         17.9 ± 35.3        0.007
   Plasma epinephrine (1--20), pg/mL          189.4 ± 381.8       219.4 ± 237.1       178.3 ± 428.1      0.813
   Plasma norepinephrine (15--80), pg/mL      1,106.6 ± 1,558.4   1,442.8 ± 1,775.6   975.1 ± 1,500.4    0.512
   Plasma metanephrine (\< 0.5), nmol/L       1.52 ± 1.41         2.28 ± 1.57         1.13 ± 1.25        0.198
   Plasma normetanephrine (\< 0.9), nmol/L    6.31 ± 6.37         4.64 ± 4.48         7.14 ± 7.27        0.547
   Secretion of catecholamine                                                                            
    Norepinephrine                            14 (38.9)           4 (50)              10 (35.7)          0.465
    Epinephrine                               56 (65.1)           18 (85.7)           38 (58.5)          0.023
    Non-secreting                             8 (22.9)            1 (12.5)            7 (25.9)           0.427
  Electrocardiographic findings                                                                          0.003
   Normal                                     78 (71.6)           15 (65.2)           63 (73.3)          
   LVH by voltage criteria                    22 (20.2)           2 (8.7)             20 (23.3)          
   Significant ST-T abnormalities             7 (6.4)             5 (21.7)            2 (2.3)            
   Nonspecific ST-T changes                   2 (1.8)             1 (4.3)             1 (1.2)            
  Echocardiographic findings                                                                             
   Study performed                            46 (41.8)           16 (69.6)           30 (34.5)          0.002
   LVEF, %                                    58.9 ± 10.0         54.3 ± 14.4         61.0 ± 6.2         0.114

Values are presented as number (%) or mean ± SD.

BUN, blood urea nitrogen; VMA, vanillyl mandelic acid; LVH, left ventricular hypertrophy; LVEF, left ventricular ejection fraction.

###### 

Clinical characteristics of patients with catecholamine cardiomyopathy associated with pheochromocytoma and paraganglioma

  No.   Age, yr   Sex      Clinical presentation                ECG findings                                                 Troponin-I, ng/mL   NT-proBNP, pg/mL   Echocardiographic pattern   LVEF, %   CAD             Time to recovery, day
  ----- --------- -------- ------------------------------------ ------------------------------------------------------------ ------------------- ------------------ --------------------------- --------- --------------- -----------------------
  1     67        Male     Chest pain, STEMI                    ST elevation in II, III, aVF and V2-6                        1.7                 2,888              Apical ballooning           29        1VD, RCA        3
  2     49        Female   Dyspnea, acute respiratory failure   ST depression in V2-6                                        6.3                 2,458              Apical ballooning           30        No              3
  3     55        Female   Chest pain                           Q wave in V1-3                                               11.7                1,546              Basal ballooning            25        No              3
  4     72        Female   Chest pain, sudden cardiac arrest    ST depression in II, III, aVF and V2-6                       15.3                27,869             Apical ballooning           30        No              4
  5     54        Male     Chest pain                           Sinus tachycardia, T wave inversion in I and aVL             6.0                 NA                 Apical ballooning           26        Mild 1VD, LAD   7
  6     62        Male     Chest pain                           Sinus tachycardia, ST depression in V4-6                     7.3                 499                Basal ballooning            47        1VD, LCX        5
  7     40        Female   Cardiogenic shock                    Sinus tachycardia, ST depression in V4-6, II, III, and aVF   10.0                562                Basal ballooning            15        NA              12

ECG, electrocardiography; NT-proBNP, N-terminal pro B-type natriuretic peptide; LVEF, left ventricular ejection fraction; CAD, coronary arterial disease; STEMI, ST-segment elevation myocardial infarction; 1VD, one vessel disease; RCA, right coronary artery; NA, not assessed; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery.

###### 

Comparison of patients presented with catecholamine cardiomyopathy and those without cardiomyopathy associated with pheochromocytoma and paraganglioma

  Variable                                   SCM (n = 7)     Non-SCM (n = 104)   *p* value
  ------------------------------------------ --------------- ------------------- -----------
  Age, yr                                    57 ± 11         51 ± 16             0.364
  Male sex                                   3 (42.9)        53 (51.5)           0.660
  Hypertension                               6 (85.7)        47 (45.7)           0.040
  Diabetes                                   3 (42.9)        17 (16.5)           0.080
  Dyslipidemia                               2 (28.6)        9 (8.7)             0.091
  At presentation                                                                
   Headache                                  2 (28.6)        15 (14.6)           0.321
   Dizziness                                 0               12 (11.7)           0.339
   Chest pain                                6 (85.7)        7 (6.8)             \< 0.001
   Palpitation                               3 (42.9)        12 (11.7)           0.020
   SBP, mmHg                                 144.7 ± 19.7    132.4 ± 23.4        0.177
   DBP, mmHg                                 91.6 ± 18.2     79.6 ± 14.5         0.041
  Paraganglioma                              0               29 (28.2)           0.102
  Maximal diameter, mm                       44.9 ± 15.4     43.5 ± 31.9         0.909
  Secretion of catecholamine                                                     
   Norepinephrine                            1 (50)          13 (38.2)           0.740
   Epinephrine                               7 (100)         49 (62.0)           0.043
   Non-secreting                             0               8 (24.2)            0.428
  Urine metanephrine (\< 0.8), mg/day        8.4 ± 5.3       120.9 ± 702.7       0.675
  Urine epinephrine (1.7--2.2), µg/day       534.8 ± 790.2   65.9 ± 186.3        0.206
  Urine norepinephrine (12.1--280), µg/day   68.0 ± 40.7     261.0 ± 327.8       0.422
  Urine VMA (\< 8), mg/day                   38.8 ± 39.6     17.9 ± 31.2         0.126
  Plasma metanephrine (\< 0.5), nmol/L       2.69 ± 2.17     1.28 ± 1.24         0.214
  Plasma normetanephrine (\< 0.9), nmol/L    2.98 ± 2.48     6.98 ± 6.78         0.444
  Echocardiography performed                 7 (100)         39 (37.9)           0.001
   LVEF, %                                   47.0 ± 17.6     61.1 ± 5.9          0.079
  After surgery                                                                  
   Antihypertensive medications              4 (57.1)        16 (15.5)           0.006
   SBP, mmHg                                 128.0 ± 11.4    123.1 ± 13.4        0.424
   DBP, mmHg                                 77.0 ± 5.1      74.9 ± 8.4          0.579

Values are presented as mean ± SD or number (%).

SCM, stress-induced cardiomyopathy; SBP, systolic blood pressure; DBP, diastolic blood pressure; VMA, vanillyl mandelic acid; LVEF, left ventricular ejection fraction.
